CheckMate -77T represents the company’s second positive Phase 3 trial with an immunotherapy-based combination for the treatment of non-metastatic non-small cell lung cancer
Positive results reinforce improved efficacy now seen in six Phase 3 trials with Opdivo-based treatments in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
https://finance.yahoo.com/news/bristol-myers-squibb-announces-perioperative-105900626.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.